G. Riley

发表

Novel and selective 5-HT2C/2B receptor antagonists as potential anxiolytic agents: synthesis, quantitative structure-activity relationships, and molecular modeling of substituted 1-(3-pyridylcarbamoyl)indolines.

S. Bromidge, S. Dabbs, D. Davies, 1998, Journal of medicinal chemistry.

A novel, potent, and selective 5-HT(7) antagonist: (R)-3-(2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-1-sulfonyl) phen ol (SB-269970).

P J Lovell, J. Hagan, D. Middlemiss, 2000, Journal of medicinal chemistry.

SB 242084, a Selective and Brain Penetrant 5-HT2C Receptor Antagonist

A. Brown, D. Middlemiss, S. Bromidge, 1997, Neuropharmacology.

Effect of Direct Injection of Melanin‐Concentrating Hormone into the Paraventricular Nucleus: Further Evidence for a Stimulatory Role in the Adrenal Axis via SLC‐1

G. Hervieu, G. Riley, S. Bloom, 2003, Journal of neuroendocrinology.

Evidence that orexin-A-evoked grooming in the rat is mediated by orexin-1 (OX1) receptors, with downstream 5-HT2C receptor involvement

G. Riley, N. Upton, R. Porter, 2000, Psychopharmacology.

5‐HT1A receptor agonist‐antagonist binding affinity difference as a measure of intrinsic activity in recombinant and native tissue systems

C. Scott, G. W. Price, G. Riley, 2000, British journal of pharmacology.

Central effects of urotensin-II following ICV administration in rats

J. Hagan, S. Douglas, G. Riley, 2001, Psychopharmacology.

The selective dopamine antagonist properties of BRL 34778: a novel substituted benzamide

G. Riley, M. Clark, P. Mitchell, 2004, Psychopharmacology.

Identification of a novel series of selective 5-HT7 receptor antagonists.

I. Forbes, G. Riley, R. Ife, 2003, Bioorganic & medicinal chemistry letters.

SB-656104-A: a novel 5-HT(7) receptor antagonist with improved in vivo properties.

I. Forbes, G. Riley, P. Jeffrey, 2002, Bioorganic & medicinal chemistry letters.

(R)-3,N-dimethyl-N-[1-methyl-3-(4-methyl-piperidin-1-yl) propyl]benzenesulfonamide: the first selective 5-HT7 receptor antagonist.

P J Lovell, J. Hagan, A. Brown, 1998, Journal of medicinal chemistry.

The selective 5-HT1B receptor inverse agonist 1'-methyl-5-[[2'-methyl-4'-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4'-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo.

J. Hagan, D. Middlemiss, G. W. Price, 1998, Journal of medicinal chemistry.

Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.

D. Middlemiss, S. Lightowler, S. Bromidge, 2000, Journal of medicinal chemistry.

Nonpeptidic urotensin‐II receptor antagonists I: in vitro pharmacological characterization of SB‐706375

David G. Behm, H. Sarau, J. Foley, 2005, British journal of pharmacology.

A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists.

S. Bromidge, F. King, G. Riley, 2005, Bioorganic & medicinal chemistry letters.

SB-236057, a selective 5-HT1B receptor inverse agonist, blocks the 5-HT human terminal autoreceptor.

D. Middlemiss, C. Scott, G. W. Price, 1999, European journal of pharmacology.

Heterocyclic analogues of 2-aminotetralins with high affinity and selectivity for the dopamine D3 receptor.

G. Riley, G. Stemp, K. Y. Avenell, 1999, Bioorganic & medicinal chemistry letters.

Fused aminotetralins: novel antagonists with high selectivity for the dopamine D3 receptor.

K. Thewlis, G. Riley, G. Stemp, 1998, Bioorganic & medicinal chemistry letters.

A novel series of 2-aminotetralins with high affinity and selectivity for the dopamine D3 receptor

K. Thewlis, G. Riley, Christopher N. Johnson, 1997 .

2-[(substituted)phenyl]-5-[1-(2-phenylazacycloheptyl)methyl]-1H-pyrroles with high affinity and selectivity for the dopamine D3 receptor

G. Riley, Stephen A. Smith, Christopher N. Johnson, 1997 .

Novel 2,5-disubstituted-1H-pyrroles with high affinity for the dopamine D3 receptor : N-benzyl modifications

G. Riley, Stephen A. Smith, Christopher N. Johnson, 1997 .

Novel 2,5-disubstituted-1H-pyrroles with high affinity for the dopamine D3 receptor

G. Riley, Christopher N. Johnson, G. Stemp, 1996 .

N-(SUBSTITUTED-PHENYL) PIPERAZINES : ANTAGONISTS WITH HIGH BINDING AND FUNCTIONAL SELECTIVITY FOR DOPAMINE D4 RECEPTORS

G. Riley, Stephen A. Smith, G. Stemp, 1996 .

Synthesis and pharmacological activity of metabolites of the 5-HT(4) receptor antagonist SB-207266.

G. Riley, G. Sanger, M. Voyle, 2001, Bioorganic & medicinal chemistry.

SB-269652 is a selective D3 receptor antagonist in vitro and in vivo

J. Hagan, G. Riley, C. Routledge, 1999, European Neuropsychopharmacology.

Design and synthesis of novel 2,3-dihydro-1H-isoindoles with high affinity and selectivity for the dopamine D3 receptor.

G. Macdonald, K. Thewlis, G. Riley, 2001, Bioorganic & medicinal chemistry letters.

Heterocyclic analogues of 2-aminotetralins with high affinity and selectivity for the dopamine D3 receptor.

G. Riley, G. Stemp, K. Y. Avenell, 1999, Bioorganic & medicinal chemistry letters.

Novel 1,2,3,4-tetrahydroisoquinolines with high affinity and selectivity for the dopamine D3 receptor.

K. Thewlis, G. Riley, G. Stemp, 1999, Bioorganic & medicinal chemistry letters.

Hippocampal and cardiovascular effects of muscarinic agents

G. Riley, M. Clark, F. Brown, 1989 .

Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives.

C. B. Naylor, G. Riley, J. Hawkins, 1992, Journal of medicinal chemistry.

Comparison of azabicyclic esters and oxadiazoles as ligands for the muscarinic receptor.

F E Blaney, P. Wyman, F. Blaney, 1991, Journal of medicinal chemistry.

The design of 8,8-dimethyl[1,6]naphthyridines as potential anticonvulsant agents.

G. Macdonald, G. Riley, N. Upton, 2003, Bioorganic & medicinal chemistry letters.

A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality

S. Bromidge, S. Dabbs, G. Riley, 1992 .

SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors.

S. Bromidge, G. Riley, J. Hawkins, 1997, The Journal of pharmacology and experimental therapeutics.

Design and synthesis of novel muscarinic agonists containing the 1,2,4-triazine ring as an ester bioisostere

G. Riley, J. Hawkins, M. Clark, 1994 .

Diaryl substituted pyrrolidinones and pyrrolones as 5-HT2C inhibitors: synthesis and biological evaluation.

G. Tedesco, G. Riley, M. Wood, 2006, Bioorganic & medicinal chemistry letters.

Substituent variation in azabicyclic triazole- and tetrazole-based muscarinic receptor ligands.

S. Bromidge, P. Wyman, G. Riley, 1992, Journal of medicinal chemistry.

5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist.

A. Brown, D. Middlemiss, S. Bromidge, 1999, Journal of medicinal chemistry.

Characterization of [125I]‐SB‐258585 binding to human recombinant and native 5‐HT6 receptors in rat, pig and human brain tissue

D. Middlemiss, G. W. Price, S. Bromidge, 2000 .

Characterization of SB‐269970‐A, a selective 5‐HT7 receptor antagonist

J. Hagan, D. Middlemiss, G. W. Price, 2000, British journal of pharmacology.

Characterization of [(125)I]-SB-258585 binding to human recombinant and native 5-HT(6) receptors in rat, pig and human brain tissue.

D. Middlemiss, G. W. Price, S. Bromidge, 2000, British journal of pharmacology.

Variation of muscarinic activities of oxotremorine analogues

G. Riley, M. Clark, R. Mcarthur, 1988 .

Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.

J. Hagan, D. Middlemiss, K. Thewlis, 2000, The Journal of pharmacology and experimental therapeutics.

Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin

Robert P. Davis, P. Murdock, G. Hervieu, 2003, Journal of neurochemistry.

SB‐656104‐A, a novel selective 5‐HT7 receptor antagonist, modulates REM sleep in rats

J. Hagan, D. Middlemiss, C. Scott, 2003, British journal of pharmacology.

SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models.

C. Regan, S. Bromidge, G. Riley, 2006, European journal of pharmacology.

Pharmacological profile of SB-357134: A potent, selective, brain penetrant, and orally active 5-HT6 receptor antagonist

G. W. Price, S. Bromidge, G. Riley, 2002, Pharmacology Biochemistry and Behavior.

Characterization of SB‐271046: A potent, selective and orally active 5‐HT6 receptor antagonist

D. Middlemiss, G. W. Price, S. Bromidge, 2000, British journal of pharmacology.

Functional effects of the muscarinic receptor agonist, xanomeline, at 5‐HT1 and 5‐HT2 receptors

D. Middlemiss, G. Riley, J. Watson, 1998, British journal of pharmacology.

Studies towards the identification of a new generation of atypical antipsychotic agents.

C. Scorer, J. Hagan, I. Forbes, 2007, Bioorganic & medicinal chemistry letters.

Bicyclic piperazinylbenzenesulphonamides are potent and selective 5-HT6 receptor antagonists.

S. Bromidge, F. King, G. Riley, 2002, Bioorganic & medicinal chemistry letters.

Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade.

C. Davies, C. Scott, G. Riley, 2006, CNS & neurological disorders drug targets.

3,4-Dihydro-2H-benzoxazinones are 5-HT(1A) receptor antagonists with potent 5-HT reuptake inhibitory activity.

D. Middlemiss, C. Scott, G. W. Price, 2005, Bioorganic & medicinal chemistry letters.

Attenuation of haloperidol‐induced catalepsy by a 5‐HT2C receptor antagonist

T. Blackburn, V. Holland, G. Riley, 1999, British journal of pharmacology.

1,2,5,6-tetrahydropyridine oxime ethers incorporating electron withdrawing groups are potent and selective muscarinic agonists

S. Bromidge, S. Dabbs, G. Riley, 1994 .

Design and synthesis of azabicyclic muscarinic agonists incorporating an oxime ether functionality

S. Bromidge, S. Dabbs, G. Riley, 1992 .

8-Piperazinyl-2,3-dihydropyrrolo[3,2-g]isoquinolines: potent, selective, orally bioavailable 5-HT1 receptor ligands.

D. Middlemiss, C. Scott, G. W. Price, 2005, Bioorganic & medicinal chemistry letters.

Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat.

J. Hagan, D. Middlemiss, K. Thewlis, 2000, Journal of medicinal chemistry.

Evidence for antagonist activity of the dopamine D3 receptor partial agonist, BP 897, at human dopamine D3 receptor.

G. Riley, M. Wood, K. Y. Avenell, 2000, European journal of pharmacology.

Novel (4-piperazin-1-ylquinolin-6-yl) arylsulfonamides with high affinity and selectivity for the 5-HT(6) receptor.

S. Bromidge, F. King, G. Riley, 2001, Bioorganic & medicinal chemistry letters.

Design and synthesis of 2-naphthoate esters as selective dopamine D4 antagonists.

J. Hagan, D. Middlemiss, G. Riley, 1996, Journal of medicinal chemistry.

SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety

D. Middlemiss, S. Lightowler, S. Bromidge, 2001, Neuropharmacology.

Model studies on a synthetically facile series of N-substituted phenyl-N'-pyridin-3-yl ureas leading to 1-(3-pyridylcarbamoyl) indolines that are potent and selective 5-HT(2C/2B) receptor antagonists.

S. Bromidge, S. Dabbs, D. Davies, 1999, Bioorganic & medicinal chemistry.

Phenyl benzenesulfonamides are novel and selective 5-HT6 antagonists: identification of N-(2,5-dibromo-3-fluorophenyl)-4-methoxy-3-piperazin-1-ylbenzenesulfonamide (SB-357134).

S. Bromidge, F. King, G. Riley, 2001, Bioorganic & medicinal chemistry letters.

Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonist.

J. Hagan, G. Macdonald, D. Middlemiss, 2003, Journal of medicinal chemistry.